In addition to their role in drug resistance, the ATP binding cassette (ABC) transporters ABCG2 and ABCB1 have been suggested to protect cells from a broad range of substances that may foster tumorigenesis. Phytoestrogens or their metabolites are substrates of these transporters and the influence of these compounds on breast cancer development is controversial. Estrogen-like properties might accelerate tumorigenesis on the one hand, while their proposed health-protective properties might antagonize tumorigenesis on the other. To address this issue, we used a newer generation mouse model of BRCA1-mutated breast cancer and examined tumor latency in K14cre,Brca1
Introduction
attractive to women with an increased risk of developing breast cancer, such as carriers of BRCA1 or BRCA2 mutations.
The polyphenolic phytoestrogens genistein and resveratrol share structural characteristics with 17β-estradiol and therefore interact with the mammalian estrogen receptors, although with lower binding affinity than estradiol itself (13, 14) .
Such estrogenic effects of phytoestrogens could alleviate discomforts of menopausal women and supplementing the diet of these women with phytoestrogens might appear an attractive alternative to estrogen-replacement therapy, which promotes breast tumorigenesis (15) . Like estrogen-replacement therapy, however, substantial estrogen-mimicking effects of phytoestrogens might also increase the risk of carcinogenesis, especially in women who have a breast cancer predisposition.
Despite several years of research, the disagreement on the positive versus negative effects of phytoestrogen-rich diets on breast cancer development remains (16, 17) . This question has been addressed using rodent models of chemically induced or xenografted tumors, but the data reported are ambiguous and did not resolve the controversy (reviewed in (12, 18)).
To tackle these issues from a different angle, we investigated the effect of genistein or resveratrol in a newer generation mouse model. K14cre;Brca1 (19) . The mammary tumors highly resemble BRCA1-associated breast cancer in humans and, like their human counterparts, these mouse tumors are "triple-negative", lacking expression of estrogen, progesterone or HER2 growth factor receptors. Despite 
Materials and Methods

Mice and special diets
To study the effect of ABC transporters on phytoestrogen disposition, the The FVB/N background or the introduction of Abcb1a/b or Abcg2 null alleles did not alter the distribution of morphologic phenotypes that were described previously (19) .
Since ABCG2 transports estrogen-sulfates (28), ABCG2 ablation may stimulate tumorigenesis indirectly through elevating endogenous estrogen levels in the mammary epithelium. A more detailed analysis of overall survival per tumor type revealed, however, that both mammary and skin tumor latency were reduced in the
Abcg2
-/-animals, indicating that the transporter effect was not mammary glandspecific ( Fig. 1D ). in near complete loss of mammary tumor development and a shift to skin tumor development, which we also observed in this study (compare Fig. 1C and Fig. 2B ). Fig. 1B and Fig. 2A Fig. 2A ). Both genistein and resveratrol reversed this ovariectomy effect (respectively P=0.004 and 0.012, Log-rank test). However, ovariectomized animals mainly developed skin tumors and if only the rate of these tumors was analysed ( Supplementary Fig. S1 ), the resveratrol effect was no longer significant, while the genistein effect still was (respectively P=0.115 and 0.037, Log-rank test).
This suggested that there may be a modest effect of genistein on preventing skin tumor formation in our model. In contrast, resveratrol may reduce the incidence of other pathological findings. Regarding tumor type distributions (Fig. 2B) , there was no effect of the phytoestrogens on mammary tumor incidence. However, there was a modest decrease in the incidence of degenerative disease or infection (genistein and resveratrol) and in the incidence of tumors, which did not originate from epithelial skin or mammary gland cells (resveratrol), such as thymoma or salivary gland adenocarcinoma (other tumors). When the relative incidences of these two death causes were compared between diet groups, the differences appeared to be appreciable, but they did not reach statistical significance (respectively P=0.10 and P=0.11, Fisher's exact test), presumably due to the low numbers. were compared between diet groups, no statistical significant differences could be detected.
Even the categories degenerative/infection or other tumors, for which there seemed to be an appreciable effect in the pie charts, no significance was reached (respectively P=0.10 and We have previously shown that lack of ABCG2 results in increased plasma levels of resveratrol and its metabolites in FVB/N mice (22). Hence, any antagonizing effects of this phytoestrogen on mammary tumor development should even be more pronounced in these ABCG2-deficient K14cre;Brca1
;p53 F/F mice. However, neither the supplementation with genistein (Fig. 3A , red line) nor with resveratrol (Fig. 3A, green line) increased the overall survival in ABCG2-deficient animals compared with their control diet litter mates (Fig. 3A , blue line). The tumor type distributions were not significantly influenced by the diet either (data not shown). This lack of dietary effects was also observed in the ABCG2-proficient animals ( Fig. 3B) , showing that diets with high concentrations of genistein or resveratrol do not retard mammary tumorigenesis in our mouse model.
Discussion
We show here that ablation of the ABC transporter ABCG2 (BCRP), but not ABCB1 (Pgp/MDR1), shortens mammary tumor latency in the K14cre;Brca1 We do not know the compound(s) and mechanism that cause the observed effects.
An unbiased, mass spectrometry-based approach (32) might be able to detect the relevant metabolite differences between the plasma or tumor tissues derived from
Abcg2
-/-versus Abcg2 +/+ animals. Moreover, it may be interesting to investigate in future experiments whether a shorter tumor latency is also found in response to ABCG2-specific inhibitors.
Our data suggest that functional ABCG2 polymorphisms might influence tumorigenesis in women with a familiar breast cancer predisposition. Of the ABCG2 single nucleotide polymorphisms (SNPs) identified, only a few influence drug transport efficiency and therefore phamacokinetics-related side effects in patients (33). The common SNP rs2231142 (421 C>A), which encodes a Q141K loss of function mutation, causes at least 10% of all gout cases in the Caucasian American population of the US (34). To our knowledge, no reports have yet been published linking ABCG2 loss-of-function SNPs to accelerated tumor progression in human BRCA1 or BRCA2 mutation carriers. Our mouse data suggest that ABCG2 dysfunction might increase the already high tumor incidence in the human population even further. Whether this effect is mammary gland-specific or also relevant to other cancer predispositions warrants further investigation.
We did not find an effect of genistein or resveratrol on mammary tumor development in our model. In other models the exposure of female Sprague-Dawley rats to 500 ppm genistein for 2 years significantly increased the risk of mammary adenocarcinoma development, but decreased the number of benign mammary fibroadenomas (35). Overall, the evidence of carcinogenic activity of genistein in female rats was determined as being "equivocal". It was also found in rats that perinatal exposure to genistein renders animals more resistant to DMBA-induced mammary tumorigenesis (36, 37), whereas no effect was seen when genistein was given to adult animals (38). These differential effects appear to be caused by In addition to a shift from mammary to skin tumor development, we observed that ovariectomy of K14cre;Brca1 F/F ;p53 F/F animals resulted in a significant (P=0.001) reduction of overall survival ( Fig. 2A) . We do not know why. There were some ovariectomized animals on the phytoestrogen-free diet that died because of degenerative or infectious causes, whereas no such cases were present in the non-ovariectomized animals. It is possible that the lack of endogenous estrogens increased the background pathology in our mouse model. Whether the animals on the pytoestrogen-supplemented diets experienced a health benefit in addition to the modest delay in skin tumor development warrants further investigation.
In summary, we found that in a genetically engineered mouse model for BRCA1-associated breast cancer ABCG2, but not ABCB1, ablation significantly reduced mammary tumor latency. This reduction was not affected by dietary supplementation with genistein or resveratrol. 
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